

Impact of first and further decompensation in patients with compensated ACLD due to MASLD

Grazia Pennisi^{1,*†}, Gabriele Di Maria^{2,†}, Vincent Wai-Sun Wong³, Victor de Ledinghen⁴, Giada Sebastiani⁵, Mauro Viganò⁶, Anna Ludovica Fracanzani^{7,8}, Luca Miele⁹, Elisabetta Bugianesi¹⁰, Mattias Ekstedt¹¹, Roberta D'Ambrosio¹², Federico Ravaioli^{13,14}, Filippo Schepis¹⁵, Fabio Marra¹⁶, Alessio Aghemo^{17,18}, Gianluca Svegliati-Baroni¹⁹, Marcello Persico²⁰, Luca Valenti^{7,21}, Annalisa Berzigotti²², Jacob George²³, Angelo Armandi¹⁰, Patrik Nasr¹¹, Stergios Kechagias¹¹, Antonio Liguori⁹, Dario Saltini¹⁵, Yuly P. Mendoza²², Vincenza Calvaruso¹, Marco Enea², Huapeng Lin³, Giuseppe Infantino¹, Mario Masarone¹⁹, Nicola Pugliese^{17,18}, Adele Tulone¹, Vito Di Marco¹, Calogero Cammà¹, Salvatore Petta¹

Journal of Hepatology 2025. vol. 83 | 1266–1277



Background & Aims: First and further decompensation events mark key transitions in the natural history of cirrhosis and significantly influence mortality risk. We assessed the cumulative incidence of first and further (acute and non-acute) decompensation and evaluated their impact on liver-related death (LR-D) in patients with compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: We conducted an international, multicenter (17 centers), retrospective study involving 6,061 consecutive patients with cACLD due to MASLD, diagnosed either clinically (liver stiffness measurement >10 kPa) or histologically (F3–F4 fibrosis). Decompensation events were defined according to the Baveno VII criteria. Cumulative incidence functions and cause-specific Cox models (with baseline and time-dependent variables) were used to analyze competing risks. A multistate model was developed to better describe the clinical trajectory of cACLD due to MASLD.

Results: The 5-year cumulative incidence of first decompensation was 3.5% (95% CI 3.0–4.1), which was associated with an 18.9-fold increase (95% CI 10.8–32.9) in the cause-specific hazard of LR-D. Among patients who experienced a first decompensation, the 5-year cumulative incidence of further decompensation was 43.9% (95% CI 37.2–50.2), further increasing the hazard of LR-D by 1.52-fold (95% CI 1.02–2.34). Ascites, followed by variceal bleeding, were the most common decompensation events. Hepatocellular carcinoma independently increased the cause-specific hazard of LR-D by 2.95-fold (95% CI 2.02–4.31) in the overall cohort and by 1.43-fold (95% CI 1.03–2.00) in patients who had experienced a first decompensation.

Conclusions: First and subsequent decompensation events are major inflection points in the clinical progression of cACLD due to MASLD, increasing the cause-specific hazard of LR-D by 18.9- and an additional 1.52-fold, respectively. Hepatocellular carcinoma is an independent predictor of LR-D and further exacerbates mortality risk when present alongside decompensation.

© 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most significant global health challenges, with a worldwide prevalence of 38% according to recent estimates,¹ and a concerning upward trend driven by the growing epidemics of diabetes and obesity.²

The widespread impact of MASLD is compounded by its potential to progress from simple steatosis to steatohepatitis (MASH), and ultimately to cirrhosis, which may be further complicated by hepatic decompensation and hepatocellular

carcinoma (HCC), often culminating in liver-related death (LR-D) or the need for liver transplantation (LT).²

It is well established that the first decompensation – defined as ascites, hepatic encephalopathy (HE), variceal bleeding, and jaundice – is a pivotal event in terms of prognosis and marks the transition from the compensated, also known as compensated advanced chronic liver disease (cACLD), to the decompensated stage of cirrhosis.³ Although only a small fraction of patients die following the first decompensation episode, the risk of developing further decompensation increases and the median survival dramatically decreases.⁴ The

* Corresponding author. Address: Grazia Pennisi, Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche, 2, 90127 Palermo, Italy. Tel.: +39 091 23890673. Fax +39 091 6552156.

E-mail address: grazia.pennisi@unipa.it (G. Pennisi).

† These authors equally contributed to the study.

<https://doi.org/10.1016/j.jhep.2025.06.014>



occurrence of a further decompensation event – defined according to the Baveno VII consensus⁵ as either the recurrence of the initial event or the development of a second decompensation event – represents a crucial turning point in the natural history of the liver disease, markedly increasing the risk of LR-D in these patients.

Recently, some experts have reasonably suggested defining the decompensation pathway occurring in patients with cirrhosis as either “acute” (AD) or “non-acute” decompensation (NAD).⁶ Although they can potentially influence the clinical outcomes of cirrhosis differently, AD and NAD currently remain theoretical constructs among patients with decompensated cirrhosis.

Although the natural course of liver disease has been extensively studied across various settings and etiologies, the impact of initial and subsequent decompensation –whether acute or non-acute – has not been specifically assessed in patients with MASLD. This scenario is particularly complex due to the dual risks involved: LR-D and a well-documented risk of extrahepatic death (EH-D) from cardiovascular events and extrahepatic cancers.⁷

The aim of our study was to assess the cumulative incidence of first and further decompensation events, acute and non-acute, and to evaluate their impact on both LR-D and EH-D in a large cohort of patients with cACLD secondary to MASLD.

Patients and methods

Study design and patient selection

This retrospective study used prospectively collected data from patients with cACLD secondary to MASLD, enrolled between 1988 and 2023 across 17 tertiary centers in Italy, France, Sweden, Canada, and China. All patients provided informed consent, and the study received approval from the respective local ethics committees. These cohorts have previously been described in studies on the natural history of MASLD.^{8,9}

Consecutive patients with either a clinical or biopsy-proven diagnosis of cACLD due to MASLD were included. cACLD was defined by a liver stiffness measurement (LSM) >10 kPa using FibroScan or by histological evidence of F3–F4 fibrosis using the Kleiner score, in accordance with Baveno VII criteria.⁵ In patients without histologic examinations, the diagnosis of MASLD required ultrasonographic detection of steatosis plus at least one criterion of the metabolic syndrome. Only patients with a follow-up of ≥6 months were included.

Exclusion criteria included age <18 years, previous history of decompensated cirrhosis and/or HCC, other liver disease etiologies (chronic hepatitis B/C, HIV infection, autoimmune hepatitis, hereditary hemochromatosis, alpha-1 antitrypsin deficiency), excessive alcohol intake (>30 g/day for men, >20 g/day for women), and extrahepatic malignancy.

Follow-up assessments included laboratory testing every 6–12 months, abdominal ultrasound or HCC screening every 6 months, and upper endoscopy according to current recommendations.^{5,10}

Decompensation definition

First decompensation was defined as the simultaneous development of ≥1 of the following events: portal hypertension-driven events (ascites, overt HE, variceal

bleeding)⁵ and/or jaundice.⁶ Ascites was diagnosed by compatible clinical signs and confirmed with ultrasound and/or diagnostic paracentesis; overt HE was classified according to West-Haven classification;¹¹ variceal bleeding was identified by upper endoscopy; jaundice was defined as bilirubin >3 mg/dl.¹²

Further decompensation was defined as the recurrence or *de novo* development of a second portal hypertension-driven decompensating event (ascites, HE or variceal bleeding) and/or jaundice.⁵

AD was defined as the development of ≥1 major complication(s): first or recurrent grade 2 or 3 ascites within less than 2 weeks, first or recurrent acute HE in patients with previously normal consciousness, and acute variceal bleeding.⁶

NAD was defined as slow ascites formation, mild grade 1 or 2 HE, or progressive jaundice in non-cholestatic cirrhosis.⁶

Patients who developed events during follow-up were evaluated for available therapies and/or for LT, as appropriate.^{13–15}

Patient evaluation

Clinical and metabolic data were collected at enrollment. The diagnosis of type 2 diabetes (T2D) was made according to the American Diabetes Association criteria,¹⁶ using a value of fasting blood glucose ≥126 mg/dl. In patients with a previous diagnosis of T2D, current medications and their changes were documented and used to confirm the diagnosis of T2D. Arterial hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, or use of blood pressure-lowering agents.¹⁷ A 12-hour overnight fasting blood sample was drawn to determine serum levels of alanine aminotransferase, albumin, and bilirubin, as well as platelet count, and international normalized ratio.

Extrahepatic events and mortality assessment

Extrahepatic events and mortality were recorded during the entire follow-up in both groups. Extrahepatic events were defined as cardiovascular events – stroke, transient ischemic attack, myocardial infarction, unstable angina – or extrahepatic cancers not including non-melanomatous skin cancers. Evidence of extrahepatic events was provided by clinical charts from emergency areas and/or hospitalization. Death was also recorded during the follow-up and classified according to associated events (liver-related, defined as LR-D, or extrahepatic-related, defined as EH-D).

Statistical analysis

Continuous variables were summarized using the median (IQR), while categorical variables were presented as frequencies and percentages. Sankey plots were utilized to illustrate the flow of major outcomes throughout patients' clinical histories, categorized by the presence and type of decompensation.

A competing risk analysis was performed to estimate the occurrence of the first decompensation, considered the event of interest, with LR-D, EH-D and LT treated as competing events. A second competing risk analysis was conducted on the subset of patients experiencing a first decompensation, with subsequent decompensation as the primary event and

LR-D, EH-D and LT as competing events. Cumulative incidence function (CIF) estimates were calculated and group comparisons were carried out using Gray’s test.¹⁸

Additional CIFs were generated by stratifying the main and competing events based on several factors:

1. Splitting both first and subsequent decompensations into AD and NAD.
2. Further categorizing first and subsequent decompensations into ascites, HE, jaundice, and variceal bleeding.
3. Differentiating deaths into liver-related and extrahepatic causes within the context of both first and subsequent decompensations.
4. Subdividing liver-related deaths due to cACLD secondary to MASLD within the framework of both first and subsequent decompensations.

The analysis of time to first decompensation began at the date of the initial diagnosis of cACLD, while the analysis of time to subsequent decompensation started from the date of the first decompensation. To ensure uniform follow-up periods across centers, 5-year CIFs were presented, with probabilities expressed as percentages throughout the text and figures.

To assess the impact of first and subsequent decompensations on LR-D – with EH-D and LT treated as competing events – and accounting for known prognostic factors and potential confounders, a multivariable analysis was performed using a cause-specific proportional hazards model with time-dependent covariates. The occurrence of the first decompensation was included as a time-dependent covariate in the linear predictor of the cACLD model, while the occurrence of subsequent decompensation was included in the model for patients who had already experienced a first decompensation. Results were expressed as hazard ratios (HRs) with 95% CIs. Additionally, the occurrence of HCC was incorporated as a time-dependent covariate in both models.

Beyond the time-dependent covariates, the cACLD model included sex, age, platelet count, albumin levels, and diabetes. In contrast, the model for first decompensation included only sex, age, and diabetes, due to the unavailability of platelet and albumin data at the time of the first decompensation.

A seven-state model was constructed, comprising cACLD as the initial state, first decompensation and subsequent decompensation as transient states, and LT, HCC-related death, LR-D, and EH-D as absorbing states. The probabilities of occupying each disease state within the multistate model were estimated using the *mstate* package in R.

All analyses were performed using R statistical software (version 4.3.3). In addition to the base R packages, the following libraries were used: *tidyverse*, *survival*, *readxl*, *grid-Extra*, *grid*, *cr17*, *gtable*, *mstate*, and *cmprsk*.

Results

Patients characteristics

Patient characteristics are listed in Table 1. Only 3.8% of patients developed HCC, while cardiovascular events and extrahepatic cancers were observed in 10.8% and 18.1% of

Table 1. Features of 6,061 patients with cACLD due to MASLD and rates of event occurrence.

Baseline characteristics of 6,061 patient with cACLD due to MASLD	
Variable	Value [missing data]
Age (*)	58 (49.8-65.5) [0]
Male sex	3,268 (53.9%) [0]
Diabetes	2,518 (41.5%) [2]
Arterial hypertension	2,201 (36.3%) [6]
Platelets – mm ³ (*)	220 (172-266) [197]
INR (*)	1 (0.9-1.1) [165]
Albumin - g/dl (*)	4.3 (4-4.5) [120]
Bilirubin - mg/dl (*)	0.6 (0.4-0.8) [117]
ALT - IU/L (*)	37 (24-63) [105]
Histological diagnosis	528 (8.7%)
Rates of event occurrence during follow-up	
First decompensation (n = 323)	
Data available on discrimination between single or multiple decompensation	313 (96.9%)
Single	226 (70.0%)
Multiple	87 (26.9%)
Data available on discrimination between acute or non-acute decompensation	274 (84.8%)
Acute	169 (61.7%)
Non-acute	105 (38.3%)
Type of first decompensation	
Data available on type of decompensating event	308 (95.4%)
Ascites	187 (3.1%)
≥2 events	31 (0.51%)
HE	36 (0.6%)
Variceal bleeding	50 (0.8%)
Jaundice	4 (0.07%)
Further decompensation in the 323 patients who experienced first decompensation (n = 132)	
Data available on discrimination between single or multiple decompensation	128 (96.9%)
Single	69 (53.9%)
Multiple	59 (46.1%)
Data available on discrimination between acute or non-acute decompensation	125 (94.7%)
Acute	58 (46.4%)
Non-acute	67 (53.6%)
Type of further decompensation	
Data available on type of decompensating event	131 (99.2%)
Ascites	42 (0.7%)
2 or more events	34 (0.6%)
HE	42 (0.7%)
Variceal bleeding	8 (0.1%)
Jaundice	5 (0.08%)
LT	51 (0.8%)
HCC	231 (3.8%)
CVE	653 (10.8%)
EHC	1,093 (18.1%)
Death	
Overall	521 (8.6%)
CV-D	56 (11.9%)
HCC-D	110 (23.6%)
LR-D	144 (30.6%)
EH-D	158 (33.8%)

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cACLD, compensated advanced chronic liver disease; CV-D, cardiovascular death; CVE, cardiovascular events; EH-D, extrahepatic death; EHC, extrahepatic cancers; GGT, gamma-glutamyltransferase; HCC, hepatocellular carcinoma; HCC-D, HCC-related death; HDL, high-density lipoprotein; HE, hepatic encephalopathy; INR, international normalized ratio; LR-D, liver-related death; LT, liver transplantation; MASLD, metabolic dysfunction-associated steatotic liver disease; TIPS, transjugular intrahepatic portosystemic shunt.

(*)Data are given as median (IQR).

patients, respectively. The first patient was enrolled in October 1988 and the last in July 2023. The median follow-up was 77.4 months (IQR 36.2–108.4 months); when stratified by center, the shortest median follow-up was 9.7 months (IQR 9.4–12.3 months) and the longest was 100.6 months (IQR 46.9–111.8 months).

Cumulative incidence of first decompensation

The Sankey Plot in Fig. S1 reports the major outcomes that occurred in the clinical history of patients according to the presence and the type of decompensation.

Three hundred and twenty-three patients experienced first decompensation in the whole cohort, 72.2% of those had a single decompensating event and 27.8% had multiple concomitant events; 61.7% experienced AD, while 38.3% experienced NAD (Table 1).

Fig. 1A shows the 5-year CIF of first decompensation, with death and LT considered as competing risks. Specifically, the cumulative incidences of first decompensation were 0.9% (95% CI 0.7–1.2), 2.6% (95% CI 2.2–3) and 3.6% (95% CI 3.0–4.1) at 1, 3 and 5 years, respectively (Table 2). The cumulative incidences of different types of first decompensation over 5 years are shown in Fig. 1B: 2.2% (95% CI 1.77–2.6) of patients experienced ascites, 0.7% (95% CI 0.48–0.97) experienced variceal bleeding and 0.5% (95% CI 0.31–0.71) experienced ≥ 2 events; HE and jaundice were reported less commonly. Baseline characteristics of patients who had ascites as first decompensation, compared to those who experienced variceal bleeding, are reported in Table S1.

Analyses using CIFs for the risk of first decompensation (according to LSM categories, presence of diabetes, ancestry, and histological/clinical diagnosis of cACLD) and for the risk of HCC (according to LSM categories and presence of diabetes) are shown in Fig. S2–7. Cause-specific Cox models for first decompensation (based on the same covariates) and for HCC occurrence (according to LSM categories and diabetes) are reported in Table S3.

Cumulative incidence of first decompensation split as AD and NAD

When focusing on the pattern of first decompensation, *i.e.* AD or NAD, data were available in 274 out of 323 patients who experienced first decompensation. Fig. 1C shows the 5-year CIF of AD and NAD with death and LT considered as competing risks, in patients with cACLD due to MASLD experiencing first decompensation. The cumulative incidences of AD at 1, 3 and 5 years were 0.5% (95% CI 0.4–0.7), 1.3% (95% CI 1–1.7) and 1.8% (95% CI 1.5–2.2), respectively, and of NAD were 0.3% (95% CI 0.15–0.41), 0.9% (95% CI 0.63–1.13) and 1.3% (95% CI 1–1.6), respectively (Table S2).

Cumulative incidence of further decompensation

Of 323 patients with cACLD due to MASLD with a first episode of decompensation, 132 developed further decompensation. Specifically, 53.9% had a single decompensating event and 46.1% had multiple events; 46.4% of patients with further decompensation experienced AD, while 53.6% experienced NAD (Table 1).

Fig. 2A shows the 5-year CIF of further decompensation, with death and LT considered as competing risks. The observed cumulative incidences of further decompensation were 23.4% (95% CI 18.6–28.6), 37.7% (95% CI 31.6–43.7) and 43.9% (95% CI 37.2–50.2) at 1, 3 and 5 years, respectively (Table 2). The cumulative incidences of different types of further decompensation over 5 years are shown in Fig. 2B: 34.9% (95% CI 29.21–39.94) of patients experienced ascites, 10.6% (95% CI 7.46–14.43) experienced variceal bleeding and 8% (95% CI 4.99–11.01) experienced ≥ 2 events; HE and jaundice were found less commonly.

Cumulative incidence of further decompensation stratified by AD and NAD

When focusing on the pattern of further decompensation, *i.e.* AD or NAD, data were available in 114 out of 132 patients who experienced further decompensation. Fig. 2C shows the 5-year CIF of AD and NAD, with death and LT considered as competing risks, in patients with cACLD due to MASLD experiencing further decompensation. The cumulative incidences of AD at 1, 3 and 5 years were 7.9% (95% CI 5–11.5), 13.4% (95% CI 9.5–18.1) and 16.7% (95% CI 11.5–21.1), respectively, and of NAD were 12% (95% CI 8.4–16.3), 20% (95% CI 15.1–24.4) and 23.2% (95% CI 17.8–29), respectively (Table S2).

Cumulative incidence of liver-related mortality at first decompensation

In patients who experienced a first decompensating event, median survival was 19.9 months (IQR 9.2–48.6). Patients who experienced ascites as a first decompensating event had a lower median survival (17.5 months; IQR 5.4–40.9) compared to those who experienced variceal bleeding (37.6 months; IQR 8.7–63.5). Fig. 3A shows the 5-year CIF of LR-D, with further decompensation, LT, and EH-D considered as competing risks. The competing risk analysis reported in Table 3 shows that LR-D occurred in 8.8% of patients (95% CI 5.9–12.3) at 1 year, 15% (95% CI 11–19.6) at 3 years, and 15.6% (95% CI 11.5–20.2) at 5 years. EH-D occurred in 5.2% of patients (95% CI 3–8.1) at 1 year, 8.2% (95% CI 5.3–11.9) at 3 years, and 12% (95% CI 7.5–15.9) at 5 years.

In the multivariable Cause-specific Cox model, first decompensation as a time-varying covariate (HR 18.94, 95% CI 10.87–32.99, $p < 0.001$), age > 60 years (HR 4.70, 95% CI 2.59–8.51, $p < 0.001$), occurrence of HCC (HR 2.95, 95% CI 2.02–4.31, $p < 0.001$), and baseline albumin < 3.5 g/dl (HR 2.03, 95% CI 1.30–3.18, $p = 0.001$) were independently associated with LR-D (Table S5).

Cumulative incidence of liver-related mortality at first decompensation stratified by AD and NAD

Fig. 3B shows the 5-year CIF of LR-D in patients with cACLD due to MASLD who experienced a first AD or NAD, with further decompensation, LT, and EH-D considered as competing risks. The cumulative incidences of LR-D at 1, 3 and 5 years were 8.1% (95% CI 4.4–13.3), 11.5% (95% CI 6.8–17.5) and 12.4% (95% CI 7.5–18.6), respectively, in patients experiencing AD, and 6.5% (95% CI 2.6–12.7), 17.1% (95% CI 9.7–

First and further decompensation in cACLD due to MASLD




Fig. 1. Five-year CIF of major events in the whole cohort with cACLD due to MASLD. (A) Five-year CIF of first decompensation, death and LT as competing events. (B) CIF of the clinical presentation of the first decompensation. (C) CIF showing the “acute” or “non-acute” presentation of first decompensation. AD, acute decompensation; cACLD, compensated advanced chronic liver disease; CIF, cumulative incidence function; HE, hepatic encephalopathy; LT, liver transplantation; NAD, non-acute decompensation. (This figure appears in color on the web.)

Table 2. Cumulative incidence of first and further decompensation at 1, 3 and 5 years, with liver-related death, extrahepatic death and LT as competing events in patients with cACLD due to MASLD.

Setting	Years	LR-D	EH-D	First decompensation	LT
cACLD	1	0.2 (0.1-0.4)	0.9 (0.7-1.2)	0.9 (0.7-1.1)	0.03 (0-0.1)
	3	0.9 (0.7-1.2)	1.8 (1.4-2.1)	2.6 (2.2-3)	0.01 (0.004-0.02)
	5	1.7 (1.3-2.1)	3.1 (2.6-3.6)	3.5 (3.0-4.1)	0.02 (0.006-0.02)
Setting	Years	LR-D	EH-D	Further decompensation	LT
First decompensation	1	11.4 (8.1-15.2)	2.0 (0.8-4.1)	23.4 (18.6-28.6)	3.5 (1.8-6.2)
	3	17.9 (13.7-22.8)	4.6 (2.5-7.6)	37.7 (31.6-43.7)	4.8 (2.7-7.9)
	5	19.2 (14.6-24.1)	7.1 (4.1-11.2)	43.9 (37.2-50.2)	5.3 (3-8.5)

cACLD, compensated advanced chronic liver disease; EH-D, extrahepatic death; LR-D, liver-related death; LT, liver transplantation; MASLD, metabolic dysfunction-associated steatotic liver disease.

Data are given as % (95% CI).

26.1) and 17.1% (95% CI 9.7-26.1), respectively, in patients experiencing NAD (Table S4).

In the multivariable cause-specific Cox model, both acute (HR 20.64, 95% CI 10.20-41.81; $p < 0.001$) and non-acute (HR 19.4, 95% CI 9.66-40.36; $p < 0.001$) first decompensation events, included as time-varying covariates, were independently associated with LR-D (Table S5).

Cumulative incidence of liver-related mortality at further decompensation

When assessing mortality rates in patients with cACLD due to MASLD who experienced further decompensation, the cumulative incidences of LR-D at 1, 3 and 5 years were 41.3% (95% CI 29-53.2), 61.9% (95% CI 48.5-72.8) and 74.6% (95% CI 59.8-82.5), respectively, which were much higher than for EH-D (12.7% [95% CI 5.9-22.3], 19% [95% CI 10.4-29.7], 20.6% [95% CI 11.6-31.5] at 1, 3 and 5 years, respectively) (Table 3). Fig. 3C shows the 5-year CIFs of LR-D and EH-D. Notably, no patients were transplanted.

In the multivariable Cause-specific Cox model, further decompensation as a time-varying covariate (HR 1.52, 95% CI 1.02-2.34, $p = 0.04$), age >60 years (HR 3.85, 95% CI 1.96-7.57, $p = 0.001$) and occurrence of HCC (HR 1.43, 95% CI 1.03-2.00, $p = 0.03$) were independently associated with LR-D (Table S5).

Cumulative incidence of liver-related mortality at further decompensation stratified by AD and NAD

Fig. 3D shows the 5-year CIF of LR-D in patients with cACLD due to MASLD who experienced further AD or NAD, with EH-D considered as a competing risk. The cumulative incidences of LR-D at 1, 3 and 5 years were 20.8% (95% CI 7.3-39), 41.7% (95% CI 21.5-60.8) and 62.5% (95% CI 34.8-76), respectively, in patients experiencing AD, and 46.2% (95% CI 26.1-64.1), 69.2% (95% CI 46.6-83.8) and 80.8% (95% CI 57.6-92.1), respectively, in patients experiencing NAD (Table S4).

In the multivariable Cause-specific Cox model, both acute (HR 1.24, 95% CI 1.01-2.04, $p = 0.04$) and non-acute (HR 1.27, 95% CI 1.02-2.01, $p = 0.04$) further decompensation events were independently associated with LR-D (Table S5).

Multistate model

To better appraise the impact of first and further decompensation on liver-related mortality in patients with cACLD due to MASLD, we built a multistate model. The model in Fig. S8A

depicts the clinical course of those patients from the cACLD state to LR-D, EH-D and LT through first and further decompensation. Interestingly, nearly 30% of patients with cACLD due to MASLD died from EH-D without developing any decompensation event. After developing the first decompensation, EH-D was lower and nearly 43% died from LR-D and 19% underwent LT. Sixteen percent of patients with cACLD experienced a further decompensation and, as expected, the proportion of LR-D increased to 54% while that of EH-D decreased.

The corresponding 5-year probabilities of state occupation for patients with cACLD due to MASLD (Fig. S8B) were: cACLD 41% (95% CI 37.3-45.0), first decompensation 6.9% (95% CI 5.0-9.3), further decompensation 6.1% (95% CI 4.2-8.7), LT 4.1% (95% CI 2.7-6.3), LR-D 8.7% (95% CI 6.6-11.5), EH-D 29.9% (95% CI 26.4-33.8) and HCC-D 3.2% (95% CI 2.0-4.9). Fig. S8C depicts the corresponding 5-year probabilities of state occupation after first decompensation: first decompensation 4.8% (95% CI 2.8-7.8), further decompensation 16.2% (95% CI 10.7-24.4), LT 19.4% (95% CI 12.5-30), LR-D 42.7% (95% CI 33.8-53.8), EH-D 17% (95% CI 11.0-26.0). Finally, among patients who experienced further decompensation, the 5-year probabilities of state occupation were: further decompensation 19% (95% CI 10.9-33.1), LT 14.5% (95% CI 7.2-29.1), LR-D 54% (95% CI 39.0-74.4) and EH-D 12.5% (95% CI 5.3-29.1) (Fig. S8D).

Discussion

This multicenter study, which included 6,061 patients with cACLD due to MASLD, demonstrates that the 5-year cumulative incidence of first decompensation was approximately 3.5%. This event was associated with an 18.9-fold increase in the cause-specific hazard of LR-D. Among patients who experienced a first decompensation, the 5-year risk of further decompensation was about 44%, which conferred a 1.52-fold increase in the cause-specific hazard of LR-D. For both first and further decompensation, ascites was the most frequent event, and the pattern of decompensation (AD vs. NAD) showed a similar impact on mortality. Additionally, the occurrence of HCC independently increased the cause-specific hazard of LR-D, regardless of hepatic decompensation.

Current literature indicates that the latency period from MASH to the appearance of cACLD may be longer than in other etiologies.¹⁹ However, once the first decompensation event occurs, the progression seems comparable to other etiologies.²⁰ Recent evidence has underscored the differing

First and further decompensation in cACLD due to MASLD




Fig. 2. Five-year CIF of major events in cACLD due to MASLD after first decompensation. (A) Five-year CIF of further decompensation, death and LT as competing events. (B) CIF of the clinical presentation of the further decompensation. (C) CIF showing the “acute” or “non-acute” presentation of further decompensation. AD, acute decompensation; cACLD, compensated advanced chronic liver disease; CIF, cumulative incidence function; HE, hepatic encephalopathy; LT, liver transplantation; NAD, non-acute decompensation. (This figure appears in color on the web.)




Fig. 3. Five-year CIF of death. (A) Five-year CIF of further decompensation, death (LR-D and EH-D) and LT in MASLD cACLD with first decompensation. (B) Five-year CIF showing the “acute” or “non-acute” presentation of first decompensation, death (LR-D and EH-D) and LT in MASLD cACLD. (C) Five-year CIF of LR-D and EH-D in MASLD cACLD with further decompensation. (D) Five-year CIF showing the “acute” or “non-acute” presentation of further decompensation, death (LR-D and EH-D) and LT in MASLD cACLD. AD, acute decompensation; cACLD, compensated advanced chronic liver disease; CIF, cumulative incidence function; EH-D, extrahepatic death; LR-D, liver-related death; LT, liver transplantation; NAD, non-acute decompensation. (This figure appears in color on the web.)

Table 3. Cumulative incidence of LR-D at 1, 3 and 5 years.

Setting	Years	LR-D	EH-D	Further decompensation	LT
First decompensation	1	8.8 (5.9-12.3)	5.2 (3-8.1)	23.7 (18-27.7)	3.6 (1.8-6)
	3	15 (11-19.6)	8.2 (5.3-11.9)	38.1 (30.9-42.8)	4.9 (2.6-7.7)
	5	15.6 (11.5-20.2)	12 (7.5-15.9)	44.3 (36.6-49.6)	5.4 (3-8.4)
Setting	Years	LR-D	EH-D	—	—
Further decompensation	1	41.3 (29-53.2)	12.7 (5.9-22.3)	—	—
	3	61.9 (48.5-72.8)	19 (10.4-29.7)	—	—
	5	74.6 (59.8-82.5)	20.6 (11.6-31.5)	—	—

cACLD, compensated advanced chronic liver disease; EH-D, extrahepatic death; LR-D, liver-related death; LT, liver transplantation; MASLD, metabolic dysfunction-associated steatotic liver disease.

Data are given as % (95% CI).

Cumulative incidence of LR-D at 1, 3 and 5 years, with further decompensation, EH-D and LT as competing events in patients with cACLD due to MASLD who experienced first decompensation (upper). Cumulative incidence at 1, 3 and 5 years of LR-D, with EH-D as a competing event in patients with cACLD due to MASLD who experienced further decompensation (bottom).

prognostic implications of first vs. further decompensation and of AD vs. NAD in patients with cACLD, but data specifically addressing these dynamics in MASLD remain limited.

Our study, conducted on a large, international cohort with purely metabolic etiology, provides new insights. Prior studies addressing similar outcomes often involved cohorts with mixed etiologies, frequently driven by alcohol or viral hepatitis.^{12,21} In our setting, competing risk analysis over 5 years revealed a low incidence (3.5%) of first decompensation, predominantly ascites, which significantly increased the hazard of LR-D – with a cumulative 5-year LR-D rate of 15.6% in these patients. Comparatively, D’Amico *et al.* reported a 5-year decompensation risk of 3% in patients without baseline varices and 28% in those with varices.²¹ These higher rates may reflect differences in etiology and disease severity, as our cohort was limited to patients with cACLD, not all cirrhotic stages. D’Amico *et al.* also reported overall 5-year mortality rates of 20% and 30% in patients without and with varices, respectively – figures comparable to the 27% cumulative 5-year LR-D and EH-D observed in our cohort following first decompensation.

We also examined further decompensation, observing a cumulative 5-year incidence of 43.9% (again, mainly ascites), which further increased the hazard of LR-D to 74.6%. This is consistent with the 52% incidence reported by D’Amico *et al.*¹² and the 39.5% found by Nouredin *et al.*²² in MASLD-related cirrhosis. However, our higher LR-D rate may stem from the low representation of viral etiology (only 9%) in our cohort, in contrast to cohorts where antiviral therapy could have improved prognosis.^{23–25} Additionally, the high burden of metabolic comorbidities may have contributed to accelerated liver disease progression and worse outcomes.²⁶

Notably, among the decompensating events, ascites was the most frequent in both the first and the further decompensation settings followed by variceal bleeding, consistent with the current literature.^{11,22} We observed a relatively low rate of HE, in contrast to a recent US cohort where HE was more prevalent²⁷ – possibly due to differences in baseline characteristics, including a higher prevalence of obesity in the US population, which may predispose to cerebrovascular events. The very low incidence of jaundice in our cohort may also inform ongoing debate, such as the Baveno VII recommendations regarding its exclusion from decompensating events.

To better depict the role of first and further decompensation in the natural history of cACLD due to MASLD, a multistate model was built. Specifically, the model showed that among

patients who experienced first decompensation, a higher proportion of them experienced liver disease progression depicted by a 5-year probability of state occupation of 4.7% for first decompensation, 16% for further decompensation, 42% for LR-D, and 19% for LT. Additionally, patients who experienced further decompensation had a poor liver-related prognosis with a 5-year probability of state occupation of 19% for further decompensation, 54% for LR-D, and 14% for LT.

A few years ago, the CANONIC²⁸ and PREDICT²⁹ studies introduced the concept of acute vs. non-acute decompensation. In our cohort, we assessed this distinction in cACLD due to MASLD, although unlike the CANONIC definition, our classification of AD excluded hospitalizations for sepsis or bacterial infection. We observed an even distribution of AD and NAD during both first and further decompensation. Notably, in first decompensation, both patterns increased the hazard of LR-D similarly, by about 20-fold, with no significant difference in risk during further decompensation. Our findings align with those by Tonon *et al.*, who also reported an even AD/NAD distribution in 617 patients with cACLD (secondary to various etiologies – only 23% had metabolic etiology).³⁰ However, unlike their study, which observed a higher impact of AD on mortality, we found a greater mortality risk associated with NAD. This may be attributed to increased patient frailty in our cohort, stemming from the presence of an active etiological trigger (as opposed to a treated/controlled viral etiology), along with a higher prevalence of metabolic comorbidities that may exacerbate liver disease progression.²⁶

Another important finding was the independent impact of HCC on LR-D. Our cause-specific Cox models, both in the full cohort and among patients with first decompensation, showed that HCC significantly increased LR-D risk. These findings emphasize the need to consider HCC not merely as a separate complication but as a disease modifier when assessing prognosis in MASLD-related cACLD.

Given the complexity of the clinical profile of patients with cACLD and MASLD, especially related to the increasing risk of extrahepatic complications (cardiovascular events and extrahepatic cancer),⁷ we also evaluated the cumulative incidence of EH-D considered as a competing risk. Notably, in our multistate model with a 5-year follow-up, we found that in patients with cACLD, EH-D occurs in approximately 30% of cases and is the leading cause of death in this population. However, this proportion decreases to 16% in patients who experience a first decompensation and further decreases to

12% in those who experience subsequent decompensation(s). Conversely, LR-D progressively becomes the leading cause of death in these patients. These data highlight the need for a comprehensive clinical assessment of extrahepatic, primarily metabolic, comorbidities in patients with advanced liver damage due to MASLD. In a systemic disease like MASLD, these comorbidities can significantly affect the prognosis independently of liver-related risks.

Noureddin *et al.* recently reported crude rates of decompensation in ~2,000 patients with MASLD. Our study adds further depth by: (1) including a larger cohort focused exclusively on cACLD; (2) providing competing risk-based estimates rather than raw data; (3) modeling mortality using time-dependent decompensation and HCC variables in cause-specific Cox regression; and (4) evaluating the impact of AD and NAD separately.

The main limitation of this study stems from its retrospective nature. Although the patients enrolled in the present study were prospectively followed, the lack of a standardized protocol and uniform follow-up limit the availability of data on weight loss and control of metabolic comorbidities. The long enrollment period may have also introduced performance bias as well as a period effect. Additionally, the study relied on secondary data derived from larger databases aimed at evaluating non-invasive test changes, which may have resulted in missing cirrhosis-specific details. These include incomplete data on recompensation, hepatic venous pressure gradient, variceal status, therapy use (non-selective beta-blockers, statins, albumin), non-invasive portal hypertension tests, portal vein thrombosis, and TIPS (transjugular intrahepatic portosystemic shunt) placement – all of which could affect

interpretation of the observed results. Another concern lies in the potentially limited external validity of our results for different populations and settings. We evaluated a cohort of patients with MASLD-related cACLD referred to tertiary referral centers and fulfilling the reported inclusion and exclusion criteria, this point being another potential source of bias. Another study limitation is the presence of missing data and potential attrition bias. Moreover, given the number of statistical tests and models performed, the possibility of false-positive findings due to multiplicity cannot be excluded. This should be considered when interpreting the significance of the associations reported. Furthermore, we did not perform separate analyses for patients with/without cirrhosis, as is common in MASH trials, while the relatively low LT rate in our cohort does not reflect the growing recognition of MASLD as a major indication for LT.³¹ Finally, data on newer HCC treatments, which may impact survival, were lacking.³²

In conclusion, our study delineates the natural history of patients with cACLD secondary to MASLD and underscores how, over a 5-year timeframe, most patients do not develop hepatic decompensation but primarily die due to extrahepatic comorbidities. Following the onset of the first decompensation, and even more after further decompensation, the risk of EH-D decreases, while the risk of LR-D progressively increases, especially in the presence of a concomitant HCC diagnosis. From a clinical standpoint, understanding the clinical course of patients with cACLD due to MASLD and profiling those patients based on the first/further decompensation and the presence or absence of HCC could prove valuable in enhancing patient care and tailoring follow-up for those at higher risk of developing complications and death.

Affiliations

¹Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE), University of Palermo, Italy; ²Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE), University of Palermo, Italy; ³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; ⁴Centre d'Investigation de la Fibrose Hépatique, INSERM U1053, Hôpital Haut-Lévêque, Bordeaux University Hospital, Pessac, France; ⁵Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal QC, Canada; ⁶Hepatology Unit, Ospedale San Giuseppe, University of Milan, Milan, Italy; ⁷Department of Pathophysiology and Transplantation, University of Milan, Italy; ⁸Unit of Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; ⁹DiSMc-Department of Scienze Mediche e Chirurgiche, Fondazione Policlinico Gemelli IRCCS, 00168 Rome, Italy; ¹⁰Division of Gastroenterology, Department of Medical Sciences, University of Torino, Torino, Italy; ¹¹Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; ¹²Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹³Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ¹⁴Department of Medical and Surgical Sciences (DIMES), University of Bologna, Bologna, Italy; ¹⁵Severe Liver Disease Unit, Azienda Ospedaliero-Universitaria di Modena and University of Modena and Reggio Emilia, Modena, Italy; ¹⁶Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Italy; Research Center DENOTHE, University of Florence, Italy; ¹⁷Department of Biomedical Sciences, Humanitas University, Milan, Italy; ¹⁸Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; ¹⁹Liver Injury and Transplant Unit, Università Politecnica delle Marche, 60121 Ancona, Italy; ²⁰Department of Medicine and Surgery, "Scuola Medica Salernitana", Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy; ²¹Translational Medicine, Department of Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico IRCCS, Milan, Italy; ²²Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; ²³Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital, University of Sydney, Westmead, New South Wales, Australia

Abbreviations

AD, acute decompensation; cACLD, compensated advanced chronic liver disease; CIF, cumulative incidence function; EH-D, extrahepatic death; HCC, hepatocellular carcinoma; LR-D, liver-related death; LR-M, liver-related mortality; LT, liver transplantation; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; NAD, non-acute decompensation.

Financial support

The research leading to these results has received funding from MIUR under PNRR M4C211.3 Heal Italia project PE0000019 CUP B73C22001250006 to

Prof. Salvatore Petta. The project is supported by Italian PNRR-MAD-2022-12375656 project. The project is supported by PRIN 2022 2022L273C9. The project is supported by RF-2021-12372399. Vincent Wong is supported by the General Research Fund from the Hong Kong SAR Government (14106824) and the Direct Grant of The Chinese University of Hong Kong (2023). Giada Sebastiani is supported by a Senior Salary Award from *Fonds de Recherche du Québec – Santé (FRQS)* (#296306). Anna Ludovica Fracanzani is supported by RF-2021-12374481. JG is supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206), Investigator and MRFF grants (APP2032407; NCRI000183; APP2016215; APP2010795; APP1196492) and a Cancer Institute, NSW grant (2021/ATRG2028).

Conflict of interest

VW served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna; and a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk, and Unilab. He has received a research grant from Gilead Sciences and is a co-founder of Illuminatio Medical Technology. SP has acted as speaker and/or advisor for AbbVie, Echosens, Gilead, MSD, Pfizer, Novonordisk, Pfizer. LV has received speaking fees from: Viatrix, Novo Nordisk, consulting fees from: Novo Nordisk, Pfizer, Boehringer Ingelheim, Resalis, and unrestricted grant support from: Gilead. RD has received speaking from AbbVie, Gilead, consulting fees from AbbVie, Gilead and Takeda. GS has acted as speaker for Merck, Gilead, Abbvie, Novo Nordisk, Pfizer, served as an advisory board member for Pfizer, Merck, Novo Nordisk, Gilead, and has received unrestricted research funding from Theratechnologies Inc. JG is supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206), Investigator and MRFF grants (APP2032407; NCRI000183; APP2016215; APP 2010795; APP1196492) and a Cancer Institute, NSW grant (2021/ATRG2028). FS as acted as speaker and/or consultant for W.L. GORE, COOK Medical, and Echosens.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

G.P., G.D.M., V.W.W., V.d.L., G.S., M.V., A.L.F., L.M., E.B., M.E., R.D., F.R., F.S., F.M., A.M.A., G.S-B, M.P., L.V., A.B., J.G., A.A., P.N., S.K., D.S., Y.P.M., V.C., M. E., L.H., G.I., M.M., N.P., A.T., V.D.M., C.C., S.P., had full control of the study design, data analysis, interpretation, and preparation of the article. All authors were involved in planning the analyses and drafting the article. The final draft article was approved by all the authors.

Data availability

Data available on request due to privacy/ethical restrictions.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2025.06.014>.

References

Author names in bold designate shared co-first authorship

- [1] **Wong VW**, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. *J Hepatol* 2023 Sep;79(3):842–852. <https://doi.org/10.1016/j.jhep.2023.04.036>. Epub 2023 May 9. PMID: 37169151.
- [2] **Estes C**, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. *J Hepatol* 2018 Oct;69(4):896–904. <https://doi.org/10.1016/j.jhep.2018.05.036>. Epub 2018 Jun 8. PMID: 29886156.
- [3] **D'Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006 Jan;44(1):217–231. <https://doi.org/10.1016/j.jhep.2005.10.013>. Epub 2005 Nov 9. PMID: 16298014.
- [4] **D'Amico G**, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. *J Hepatol* 2018 Mar;68(3):563–576. <https://doi.org/10.1016/j.jhep.2017.10.020>. Epub 2017 Oct 27. PMID: 29111320.
- [5] **de Franchis R**, Bosch J, Garcia-Tsao G, et al. Baveno VII - renewing consensus in portal hypertension. *J Hepatol* 2022 Apr;76(4):959–974. <https://doi.org/10.1016/j.jhep.2021.12.022>. Epub 2021 Dec 30. Erratum in: *J Hepatol*. 2022 Apr 14; PMID: 35120736.
- [6] **D'Amico G**, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. *J Hepatol* 2022 Jan;76(1):202–207. Erratum in: *J Hepatol* 2022 Jan 5.
- [7] **Pennisi G**, Enea M, Romero-Gomez M, et al. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. *Aliment Pharmacol Ther* 2022 Mar;55(5):604–615. <https://doi.org/10.1111/apt.16763>. Epub 2022 Jan 5. PMID: 34988994.
- [8] **Lin H**, Lee HW, Yip TC, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. *JAMA* 2024 Apr 16;331(15):1287–1297. <https://doi.org/10.1001/jama.2024.1447>. PMID: 38512249; PMCID: PMC10958386.
- [9] **Zhou XD**, Kim SU, Yip TC, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. *Gut* 2024 Oct 7;73(11):1883–1892. <https://doi.org/10.1136/gutjnl-2024-333074>. PMID: 39089860.
- [10] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018 Jul;69(1):182–236. <https://doi.org/10.1016/j.jhep.2018.03.019>.
- [11] **Ferenci P**, Lockwood A, Mullen K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 2002 Mar;35(3):716–721. <https://doi.org/10.1053/jhep.2002.31250>. PMID: 11870389.
- [12] **D'Amico G**, Zipprich A, Villanueva C, et al. Further decompensation in cirrhosis: results of a large multicenter cohort study supporting Baveno VII statements. *Hepatology* 2024 Apr 1;79(4):869–881. <https://doi.org/10.1097/HEP.0000000000000652>. Epub 2023 Nov 2. PMID: 37916970.
- [13] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010 Sep;53(3):397–417.
- [14] **Garcia-Tsao G**, Sanyal AJ, Grace ND, et al. Practice guidelines committee of the American association for the study of liver diseases; practice parameters committee of the American college of gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* 2007 Sep;46(3):922–938.
- [15] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018 Aug;69(2):406–460.
- [16] Introduction: standards of medical care in diabetes-2020. *Diabetes Care* 2020 Jan;43(Suppl 1):S1–S2. <https://doi.org/10.2337/dc20-Sint>. PMID: 31862741.
- [17] **Williams B**, Mancia G, Spiering W, et al., ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018 Sep 1;39(33):3021–3104. <https://doi.org/10.1093/eurheartj/ehy339>. Erratum in: *Eur Heart J*. 2019 Feb 1;40(5):475. PMID: 30165516.
- [18] **Gray RJ**. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat* 1988;1141–1154.
- [19] **Sanyal AJ**, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *N Engl J Med* 2021 Oct 21;385(17):1559–1569. <https://doi.org/10.1056/NEJMoa2029349>. PMID: 34670043; PMCID: PMC8881985.
- [20] **Allen AM**, Therneau TM, Ahmed OT, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. *J Hepatol* 2022 Nov;77(5):1237–1245. <https://doi.org/10.1016/j.jhep.2022.07.004>. Epub 2022 Jul 16. PMID: 35843374; PMCID: PMC9974107.
- [21] **D'Amico G**, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. *Aliment Pharmacol Ther* 2014 May;39(10):1180–1193. <https://doi.org/10.1111/apt.12721>. Epub 2014 Mar 24. PMID: 24654740.
- [22] **Noureddin N**, Huang DQ, Bettencourt R, et al. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. *Aliment Pharmacol Ther* 2024 Jun;59(12):1521–1526. <https://doi.org/10.1111/apt.17981>. Epub 2024 Apr 3. PMID: 38571305.
- [23] **Krassenburg LAP**, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. *J Hepatol* 2021 May;74(5):1053–1063. <https://doi.org/10.1016/j.jhep.2020.11.021>. Epub 2020 Nov 23. PMID: 33242501.
- [24] **Lens S**, Alvarado-Tapias E, Mariño Z, et al. Effects of all-oral anti-viral therapy on HVPg and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. *Gastroenterology* 2017 Nov;153(5):1273–1283. e1. <https://doi.org/10.1053/j.gastro.2017.07.016>. Epub 2017 Jul 20. PMID: 28734831.
- [25] **Lens S**, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J Hepatol* 2020 Dec;73(6):1415–1424. <https://doi.org/10.1016/j.jhep.2020.05.050>. Epub 2020 Jun 12. PMID: 32535060.
- [26] **Targher G**, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. *Gut* 2024 Mar 7;73(4):691–702. <https://doi.org/10.1136/gutjnl-2023-330595>. PMID: 38228377.
- [27] **Sanyal AJ**, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *N Engl J Med* 2021 Oct 21;385(17):1559–1569. <https://doi.org/10.1056/NEJMoa2029349>. PMID: 34670043; PMCID: PMC8881985.

- [28] **Moreau R**, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013 Jun;144(7):1426–1437. <https://doi.org/10.1053/j.gastro.2013.02.042>. 1437.e1-1437.
- [29] **Trebicka J**, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. *J Hepatol* 2020 Oct;73(4):842–854. <https://doi.org/10.1016/j.jhep.2020.06.013>. Epub 2020 Jul 13. PMID: 32673741.
- [30] **Tonon M**, D'Ambrosio R, Calvino V, et al. A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis. *J Hepatol* 2024 Apr;80(4):603–609. <https://doi.org/10.1016/j.jhep.2023.12.005>. Epub 2023 Dec 17. PMID: 38110003.
- [31] **Terrault NA**, Francoz C, Berenguer M, et al. Liver transplantation 2023: status report, current and future challenges. *Clin Gastroenterol Hepatol* 2023 Jul;21(8):2150–2166. <https://doi.org/10.1016/j.cgh.2023.04.005>. Epub 2023 Apr 20. PMID: 37084928.
- [32] **Foerster F**, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. *J Hepatol* 2022 Feb;76(2):446–457. <https://doi.org/10.1016/j.jhep.2021.09.007>. Epub 2021 Sep 20. PMID: 34555422.

Keywords: MASLD; Cirrhosis; Decompensation; Complications; Mortality.

Received 18 July 2024; received in revised form 11 June 2025; accepted 15 June 2025; available online 21 June 2025

Supplemental information

Impact of first and further decompensation in patients with compensated ACLD due to MASLD

Grazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, Victor de Ledinghen, Giada Sebastiani, Mauro Viganò, Anna Ludovica Fracanzani, Luca Miele, Elisabetta Bugianesi, Mattias Ekstedt, Roberta D'Ambrosio, Federico Ravaioli, Filippo Schepis, Fabio Marra, Alessio Aghemo, Gianluca Svegliati-Baroni, Marcello Persico, Luca Valenti, Annalisa Berzigotti, Jacob George, Angelo Armandi, Patrik Nasr, Stergios Kechagias, Antonio Liguori, Dario Saltini, Yuly P. Mendoza, Vincenza Calvaruso, Marco Enea, Huapeng Lin, Giuseppe Infantino, Mario Masarone, Nicola Pugliese, Adele Tulone, Vito Di Marco, Calogero Cammà, and Salvatore Petta

Impact of first and further decompensation in patients with compensated ACLD due to MASLD

Grazia Pennisi, Gabriele Di Maria, Vincent Wai-Sun Wong, Victor de Ledinghen, Giada Sebastiani, Mauro Viganò, Anna Ludovica Fracanzani, Luca Miele, Elisabetta Bugianesi, Mattias Ekstedt, Roberta D'Ambrosio, Federico Ravaioli, Filippo Schepis, Fabio Marra, Alessio Aghemo, Gianluca Svegliati-Baroni, Marcello Persico, Luca Valenti, Annalisa Berzigotti, Jacob George, Angelo Armandi, Patrik Nasr, Stergios Kechagias, Antonio Liguori, Dario Saltini, Yuly P. Mendoza, Vincenza Calvaruso, Marco Enea, Huapeng Lin, Giuseppe Infantino, Mario Masarone, Nicola Pugliese, Adele Tulone, Vito Di Marco, Calogero Cammà, Salvatore Petta

Table of contents

Supplementary tables.....	2
Supplementary figures.....	7

Supplementary tables

Table S1. Baseline features of patients with cACLD due to MASLD who experienced ascites and variceal bleeding.

Variable	Ascites (n=187)	Variceal bleeding (n=50)
Age (*)	66.3 (60-73)	68.5 (60.5-74.8)
Male gender	110 (58.8%)	26 (52 %)
Obesity	83 (51.5%)	19 (44.2%)
Diabetes	118 (63.1%)	33 (66%)
Arterial Hypertension	114 (60.9%)	26 (52%)
Fasting glucose - mg/dL (*)	116 (99-142)	114 (91-139)
Total Cholesterol - mg/dL (*)	174 (145–206)	191 (153–202)
Triglycerides - mg/dL (*)	123 (89.1–156)	130 (112–180)
HDL - mg/dL (*)	45 (39–55)	41 (35–47.5)
Platelets – mmc (*)	128 (83–177)	113 (76.2–242)
INR (*)	1.16 (1.06–1.3)	1.13 (1.07–1.3)
Albumin - g/dL (*)	3.8 (3.48–4.17)	3.9 (3.6–4.1)
Bilirubin - mg/dL (*)	1.08 (0.697–1.4)	1 (0.7–1.21)
AST - UI/L (*)	46 (34.2–65)	41 (32–61)
ALT - UI/L (*)	40 (27–57)	40 (25–54)
GGT - UI/L (*)	15 (70-226)	84 (58–141)
ALP - UI/L (*)	130 (93.2-169)	108 (86.2–142)

cACLD, compensated advanced chronic liver disease; MASLD, metabolic-dysfunction associated steatotic liver disease; HDL, high-density lipoprotein; INR, international normalized ratio; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase.

Data are given as (*) median (interquartile range).

Table S2. Cumulative incidence at 1, 3 and 5 years of first and further decompensation split into AD and NAD, with death and LT as competing events in patients with cACLD due to MASLD.

Setting	Years	LR-D	EH-D	LT	AD	NAD
<i>cACLD</i>	1	0.2 (0.1-0.3)	0.9 (0.7-0.12)	0.03 (0.001-0.1)	0.5 (0.4-0.7)	0.3 (0.15-0.41)
	3	0.9 (0.7-1.2)	1.8 (1.4-2.2)	0.11 (0.04-0.2)	1.3 (1-1.7)	0.9 (0.63-1.13)
	5	1.7 (1.3-2.1)	3.1 (2.6-3.6)	0.02 (0.06-0.27)	1.8 (1.5-2.2)	1.3 (1-1.6)
Setting	Years	LR-D	EH-D	LT	AD	NAD
<i>First decompensation</i>	1	12.5 (8.9-16.7)	2.2 (0.9-4.5)	3.76 (1.9-6.6)	7.9 (5-11.5)	12 (8.4-16.3)
	3	19.6 (14.9-24.7)	4.9 (2.7-8.2)	5.1 (2.8-8.3)	13.4 (9.5-18.1)	20 (15.1-24.4)
	5	20.8 (16.0-26.2)	7.6 (4.4-11.9)	5.6 (3.2-9)	16.7 (11.5-21.1)	23.2 (17.8-29)

Abbreviations: cACLD, compensated advanced chronic liver disease; MASLD, metabolic-dysfunction associated steatotic liver disease; LT, liver transplantation; AD, acute decompensation; NAD, non-acute decompensation.
Data are given as %.

Table S3. Competing risk analysis (cause-specific Cox) assessing the effect of LSM, diabetes, race, and type of cACLD diagnosis on the cause-specific hazard of first decompensation, and of LSM and diabetes on the cause-specific hazard of HCC in patients with cACLD due to MASLD.

Setting	Variables	HR	95% C.I.	P value
Outcome: First decompensation*				
<i>cACLD</i>	LSM >15-20 KPa vs <15	5.72	(3.47-9.42)	<0.001
	LSM >20-25 KPa vs <15	5.24	(3.03-9.06)	<0.001
	LSM >25 KPa vs <15	7.41	(4.74-11.5)	<0.001
	LSM >30.7 KPa vs. ≤30.7 KPa	2.25	(1.58-3.21)	<0.001
	Diabetes	1.16	(0.88-1.54)	0.27
	Nonasiatic vs Asiatic population	6.15	(4.01-9.43)	<0.001
	Histological vs Clinical diagnosis	1.38	(1.00-1.91)	0.04
	LSM 15-20 KPa vs <15 in Asiatic patients	8.69	(2.52–29.9)	<0.001
	LSM >20-25 KPa vs <15 in Asiatic patients	9.70	(2.04-46.1)	0.004
	LSM >25 KPa vs <15 in Asiatic patients	20.3	(7.24–57.4)	<0.001
LSM >30.7 KPa vs. ≤30.7 KPa in Asiatic patients	8.81	(3.15-24.6)	<0.001	
LSM >15-20 KPa vs <15 in nonasiatic patients	2.48	(1.44–4.23)	<0.001	
LSM >20-25 KPa vs <15 in nonasiatic patients	2.21	(1.24-3.93)	0.006	
LSM >25 KPa vs <15 in nonasiatic patients	3.05	(1.92-4.84)	<0.001	
LSM >30.7 KPa vs. ≤30.7 KPa in nonasiatic patients	1.55	(1.08-2.32)	0.01	
Outcome: Hepatocellular carcinoma				
<i>cACLD</i>	Diabetes	1.63	(1.21-2.21)	0.001
	LSM 15-20 KPa vs <15	4.63	(3.02-7.12)	<0.001
	LSM >20-25 KPa vs <15	4.18	(2.53-6.90)	<0.001
	LSM >25 KPa vs <15	3.84	(2.54-5.81)	<0.001
	LSM >30.7 KPa vs ≤30.7	2.04	(1.39-3.00)	<0.001

* Models adjusted for the variables object of investigation and for age>60 years, PLT>150/mm³, diabetes, albumin <3.6 g/dL
Abbreviations: cACLD, compensated advanced chronic liver disease; MASLD, metabolic-dysfunction associated steatotic liver disease; PLT, platelets.

Table S4. Cumulative incidence at 1, 3, and 5 years of LR-D, with further decompensation, EH-D, and LT as competing events in patients with cACLD due to MASLD who experienced first decompensation, stratified by AD and NAD (upper panel). Cumulative incidence at 1, 3, and 5 years of LR-D, with EH-D as a competing event in patients with cACLD due to MASLD who experienced further decompensation, stratified by AD and NAD (bottom panel).

Setting	Years	LR-D	EH-D	LT	Further decompensation
<i>First acute decompensation</i>	1	8.1 (4.4-13.3)	3.7 (1.4-7.9)	2.7 (0.9-6.4)	23.2 (16.6-30.5)
	3	11.5 (6.8-17.5)	6.2 (2.9-11.3)	4.5 (1.8-9.1)	40.1 (31.2-48.8)
	5	12.4 (7.5-18.6)	8.7 (4.3-15.1)	5.5 (2.4-10.6)	46.9 (37-56.2)
<i>First non-acute decompensation</i>	1	6.5 (2.6-12.7)	2.1 (0.4-6.8)	1.1 (0.1-5.3)	23.4 (15.2-32.6)
	3	17.1 (9.7-26.1)	5 (1.6-11.4)	2.2 (0.4-7)	36.5 (26.1-46.9)
	5	17.1 (9.7-26.1)	5 (1.6-11.4)	2.2 (0.4-7)	43.9 (32.1-55)
Setting	Years	LR-D	EH-D	LT	Further decompensation
<i>Further acute decompensation</i>	1	20.8 (7.3-39)	20.8 (7.3-39.1)	-	-
	3	41.7 (21.5-60.8)	29.2 (12.5-48.2)	-	-
	5	62.5 (34.8-76)	33.3 (15.3-52.6)	-	-
<i>Further non-acute decompensation</i>	1	46.2 (26.1-64.1)	0	-	-
	3	69.2 (46.6-83.8)	7.7 (1.2-22.5)	-	-
	5	80.8 (57.6-92.1)	11.5 (2.6-27.9)	-	-

Abbreviations: cACLD, compensated advanced chronic liver disease; MASLD, metabolic-dysfunction associated steatotic liver disease; LT, liver transplantation; LR-D, liver-related death; EH-D, extra-hepatic death; AD, acute decompensation; NAD, non-acute decompensation.
Data are given as %.

Table S5. Competing risk analysis (cause-specific Cox) of variables associated with the cause-specific hazard of LR-D at first and further decompensation and both split into AD and NAD in cACLD due to MASLD.

Setting	Variables	HR	95% C.I.	P value
<i>cACLD with occurrence of first decompensation</i>	Male	1.39	0.97-1.98	0.069
	Age >60 years	4.70	2.59-8.51	<0.001
	PLT <150/mm ³	0.85	0.54-1.32	0.47
	Diabetes	0.95	0.67-1.36	0.81
	HCC*	2.95	2.02-4.31	<0.001
	Albumin <3.5 g/dL	2.03	1.30-3.18	0.001
	First decompensation*	18.94	10.87-32.99	<0.001
<i>cACLD with occurrence of first AD and NAD</i>	Male	1.66	1.09-2.53	0.01
	Age >60 years	4.76	2.51-9.03	<0.001
	PLT <150/mm ³	0.69	0.40-1.17	0.17
	Diabetes	0.92	0.61-1.36	0.68
	HCC*	3.64	2.33-5.66	<0.001
	Albumin <3.5 g/dL	1.94	1.21-3.10	0.005
	AD*	20.64	10.19-41.81	<0.001
NAD*	19.4	9.66-40.35	<0.001	
<i>First decompensation with occurrence of further decompensation</i>	Male	1.43	0.96-2.13	0.07
	Age >60 years	3.85	1.96-7.57	<0.001
	Diabetes	0.84	0.56-1.25	0.40
	HCC*	1.43	1.03-2.00	0.03
	Further decompensation*	1.52	1.02-2.34	0.04
<i>First decompensation with occurrence of further AD and NAD</i>	Male	1.56	0.98-2.51	0.06
	Age >60 years	3.35	1.65-6.81	0.001
	Diabetes	1.04	0.67-1.62	0.84
	HCC*	1.63	1.14-2.33	0.006
	AD*	1.24	1.01-2.04	0.04
	NAD*	1.27	1.02-2.01	0.04


*Included as time-dependent covariate.

Abbreviations: cACLD, compensated advanced chronic liver disease; MASLD, metabolic-dysfunction associated steatotic liver disease; AD, acute decompensation; NAD, non-acute decompensation; HCC, hepatocellular carcinoma; PLT, platelets.

Supplementary figures

Fig. S1. The Sankey Plot reporting the major outcomes that occurred in the clinical history of MASLD cACLD patients.

cACLD, compensated advanced chronic liver disease; LT, liver transplantation; HCC, hepatocellular carcinoma; CVE, cardiovascular events; EHC, extra-hepatic cancer; LR-D, liver-related death; EH-D, extra-hepatic death.




	0	1	2	3	4	5
N patients at risk	5834	5502	4780	4347	3883	3404
<10	0	0	3	5	5	5
10-15	0	3	9	15	17	17
15-20	0	10	17	25	26	30
20-25	0	6	11	15	16	17
> 25	0	22	40	49	61	69

Gray test: <0.001

Fig. S2. Five-year CIF of first decompensation in cACLD due to MASLD according to LSM categories (<10 KPa, 10-15 KPa, 15-20 KPa, 20-25 KPa, \geq 25 KPa).


cACLD, compensated advanced chronic liver disease; LSM, liver stiffness measurement.



	0	1	2	3	4	5
N patients at risk	5836	5504	4781	4348	3884	3405
NO	0	26	52	77	84	92
YES	0	15	29	33	42	47

Fig. S3. Five-year CIF of first decompensation in cACLD due to MASLD according to LSM >30.7 KPa.

cACLD, compensated advanced chronic liver disease; LSM, liver stiffness measurement.




	0	1	2	3	4	5
N patients at risk	6059	5703	4963	4504	4026	3528
NO	0	20	46	62	70	78
YES	0	33	54	78	91	103

Gray test: <0.001

Fig. S4. Five-year CIF of first decompensation in cACLD due to MASLD according to the presence or absence of diabetes.

cACLD, compensated advanced chronic liver disease.

A



Gray test: <0.001

N patients at risk	0	1	2	3	4	5
Asian	6061	5704	4964	4505	4027	3529
Non-Asian	0	5	14	18	20	22
	0	48	86	122	141	159

B






Fig. S5. Five-year CIF of first decompensation in cACLD due to MASLD according to (A) ancestry and (B) both ancestry and LSM categories (<10 KPa, 10-15 KPa, 15-20 KPa, 20-25 KPa, \geq 25 KPa). *cACLD*, compensated advanced chronic liver disease; *LSM*, liver stiffness measurement.




							Gray test: <0.001
N patients at risk	6012	5669	4941	4487	4014	3518	
Clinical	0	38	79	109	119	136	
Histological	0	12	17	27	37	40	

Fig. S6. Five-year CIF of first decompensation in cACLD due to MASLD according to the histological or clinical diagnosis of the disease.

cACLD, compensated advanced chronic liver disease.

A



B






Fig. S7. Five-year CIF of HCC in cACLD due to MASLD according to (A) LSM categories (<10 KPa, 10-15 KPa, 15-20 KPa, 20-25 KPa, \geq 25 KPa) and (B) the presence or absence of diabetes. *cACLD*, compensated advanced chronic liver disease; *HCC*, hepatocellular carcinoma; *LSM*, liver stiffness measurement


A



B



C



D




Fig. S8. (A) Multistate model summarizing the clinical course in patients with cACLD due to MASLD. Arrows represent transitions across the clinical states. Numbers close to the arrows are the 5-years transition rate assessed by competing risk analysis. (B) Five-year occupation probability of state occupation of patients with cACLD due to MASLD. (C) Five-year occupation probability of state occupation of patients with cACLD due to MASLD at first decompensation. (D) Five-year occupation probability of state occupation of patients with cACLD due to MASLD at further decompensation.

cACLD, compensated advanced chronic liver disease; LT, liver transplantation; HCC-D, hepatocellular carcinoma-related death; LR-D, liver-related death; EH-D, extra-hepatic death.